Advertisement

Topics

Amgen AB Company Profile

15:33 EDT 19th September 2018 | BioPortfolio

Amgen är ett världsledande bioteknologiskt läkemedelsföretag. Genom vetenskapliga upptäckter och innovationer har företaget under 25 års tid bidragit till att radikalt förbättra människors liv.
Amgen är föregångare i utvecklingen av nya produkter baserade på rekombinant DNA-teknik och molekylärbiologi och stod för lanseringen av bioteknikindustrins första storsäljande läkemedel. Som ett Fortune 500-företag vars produkter betjänar miljontals patienter fortsätter Amgen idag att med entreprenörsanda och vetenskap som drivkrafter hjälpa människor i kampen mot svåra sjukdomar

Location

Besöksadress: Rålambsvägen 17Box 34107
Stockholm
100 26
Sweden

Contact

Phone: 08-695 11 00
Fax: 08-695 11 01


News Articles [484 Associated News Articles listed on BioPortfolio]

Amgen Spain: Success in Europe

In this episode of PharmaTelevision News Review, Fintan Walton talks with Jordi Marti, CEO at Amgen Spain. Filmed at Bio-Europe Spring 2010 in Barcelona, Spain, they discuss: • Why Amgen decided to...

Amgen To Present At The Morgan Stanley Global Healthcare Conference

THOUSAND OAKS, Calif., Sept. 7, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on Wednesday, Sept. 12, 2018, in New York Cit...

Amgen To Present At The Bank of America Merrill Lynch 2018 Health Care Conference

THOUSAND OAKS, Calif., May 10, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2018 Health Care Conference at 10 a.m. PT on Tuesday, May 15, 2018. David W. M...

Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference

THOUSAND OAKS, Calif., Sept. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9 a.m. GMT on Friday, Sept. 14, 2018, in Lo...

Amgen To Present At the Cowen and Company 38th Annual Health Care Conference

THOUSAND OAKS, Calif., March 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 38th Annual Health Care Conference at 1:30 p.m. ET on Monday, March 12, 2018, in Boston. ...

Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

THOUSAND OAKS, Calif., June 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 39th Annual Global Healthcare Conference at 9:30 a.m. PT on Tuesday, June 12, 2018, in Rancho...

Amgen signs 2 oncology deals with MD Anderson

Amgen and the University of Texas MD Anderson Cancer Center are partnering on two multiyear collaborations to develop Amgen's -More- 

Amgen Offering Golden Ticket for Biotech Startups

Once again, Amgen is accepting submissions for the 2018 Amgen-LabCentral Golden Ticket competition.

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Nplate [Amgen Inc]

These highlights do not include all the information needed to use Nplate safely and effectively. See full prescribing information for Nplate. Nplate (romiplostim)For subcutaneous injection Initial U.S...

Neulasta [AMGEN INC]

These highlights do not include all the information needed to use Neulasta safely and effectively. See full prescribing information for Neulasta. Neulasta (pegfilgrastim) injection, for subcutaneous u...

Neulasta [Physicians Total Care, Inc.]

These highlights do not include all the information needed to use Neulasta safely and effectively. See full prescribing information for Neulasta.Neulasta (pegfilgrastim) injection, for subcutaneous us...

Sensipar [Amgen, Inc]

These highlights do not include all the information needed to use Sensipar safely and effectively. See full prescribing information for Sensipar. Sensipar (cinacalcet) TabletsInitial U.S. Approval: 20...

Xgeva [AMGEN]

These highlights do not include all the information needed to use XGEVA™ safely and effectively. See full prescribing information for XGEVA. Xgeva (denosumab)injection, for subcutaneous useInitial U...

PubMed Articles [4 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Local Administration of Interleukin-1 Receptor Antagonist Improves Diabetic Wound Healing.

Impaired healing of the skin is a notable cause of patient morbidity and mortality. In diabetic individuals, dysregulated inflammation contributes to delayed wound healing. Specific immunomodulatory a...

A closer look at blinatumomab.

On March 29, 2018, blinatumomab (Blincyto, Amgen) received an accelerated expanded approval for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) w...

Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.

ABP 215 is a biosimilar product to bevacizumab. Bevacizumab acts by binding to vascular endothelial growth factor A, inhibiting endothelial cell proliferation and new blood vessel formation, thereby l...

Clinical Trials [18 Associated Clinical Trials listed on BioPortfolio]

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

The purpose of this study is to demonstrate therapeutic equivalence of subcutaneous (SC) Epoetin Hospira compared to SC Epogen (Amgen,) based on maintenance of hemoglobin (Hb) levels and s...

An Open Label Treatment Extension Study of AMG 706

This is an extension study to provide ongoing treatment with AMG 706 monotherapy for subjects with solid tumors who have completed the planned duration of AMG 706 treatment on a separate A...

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

The purpose of this study is to assess the safety, tolerability, and utility of AMG 531 unit dosing (µg) in thrombocytopenic subjects with ITP.

Study To Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation

The purpose of this study is to collect local laboratory data on immunoreactive parathyroid hormone (iPTH), calcium and phosphorus levels and estimated glomerular filtration rate (GFR) at ...

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

5-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation. EPOCH: Etoposide, VP-16, NSC-141540; Prednisone, PRED, NSC-10023; Vincristine, VCR, NSC-67574; Cyclophosphamide, CTX...

Companies [48 Associated Companies listed on BioPortfolio]

Amgen, Inc.

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bri...

Amgen Inc.

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bri...

Amgen

The Amgen Foundation (www.amgen.com/citizenship/overview.html) seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live...

Amgen AB

Amgen är ett världsledande bioteknologiskt läkemedelsföretag. Genom vetenskapliga upptäckter och innovationer har företaget under 25 års tid bidragit till att radikalt förbättra människors l...

Amgen Inc

Amgen is a leading human therapeutics company in the biotechnology industry. For 25 years, the company has tapped the power of scientific discovery and innovation to dramatically improve people’s li...

More Information about "Amgen AB" on BioPortfolio

We have published hundreds of Amgen AB news stories on BioPortfolio along with dozens of Amgen AB Clinical Trials and PubMed Articles about Amgen AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Amgen AB Companies in our database. You can also find out about relevant Amgen AB Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...


Corporate Database Quicklinks



Searches Linking to this Company Record